Amarin Revives Patent Suit Against Hikma for Vascepa Generic (1)

Amarin Pharma Inc. revived its patent suit against rival Hikma Pharmaceuticals USA Inc. over the marketing and labeling of a generic version of Amarin’s billion-dollar drug Vascepa, after the Federal Circuit overturned a lower court decision tossing the case.

Amarin alleged that Hikma’s “skinny” label for and press releases about its Vascepa generic induced infringement of two Amarin patents covering Vascepa’s use as a treatment for heart disease.

In a precedential opinion issued Tuesday, the US Court of Appeals for the Federal Circuit said Hikma’s label alone, which didn’t expressly instruct that the generic should be prescribed for heart disease, ...